Acrivon Therapeutics (ACRV)
Develops cancer therapies and companion diagnostics around drug-specific proteomic patient selection.
Something off on this page? Send us feedback.
Develops oncology therapies with companion diagnostics that use the AP3 platform and drug-specific OncoSignature tests to identify patients whose tumors are predicted to respond. Its clinical pipeline centers on ACR-368 and internally discovered programs, without approved products or commercial sales infrastructure.
Builds targeted cancer-therapy candidates through AP3, a generative phosphoproteomics platform that interprets drug-regulated pathway activity in intact cells. The resulting data guide rational drug design and drug-specific OncoSignature tests that select patients whose tumors are predicted to be sensitive.
ACR-368 is the most advanced program, undergoing registrational-intent development in endometrial cancer; ACR-2316 is an internally discovered WEE1/PKMYT1 inhibitor in early clinical development, with other AP3-enabled programs preclinical. The business has no approved products, sales, marketing, or distribution infrastructure and depends on clinical development, diagnostic validation, third-party manufacturing, and future commercial capabilities or partnerships.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| May 16, 2025 | Jones Trading | Downgrade | Buy | Hold |
| Sep 16, 2024 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $90.0M · Total debt $2.1M · Total assets $99.1M · Shareholders' equity $86.7M
- Revenue
- $0
- Operating income
- −$18.7M
- Net income
- −$18.0M
No dividends on record.
| Institutions43 holders · as of Mar 31, 2026 | 37.89% | 16.24M shares | |
| Insiders15 holders · as of Sep 2, 2026 | 7.31% | 3.13M shares | |
| Otherremainder | 54.80% | 23.49M shares |
42.85M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 19.46% | 8.34M | 13Fas of Mar 31, 2026 |
Peter Blume-JensenInsiderdirector, officer: President and CEO | 6.10% | 2.62M | Form 4filed Aug 27, 2026 ↗ |
Sands Capital Ventures, LLCInstitution | 4.95% | 2.12M | 13Fas of Mar 31, 2026 |
Wellington Management Group LLPInstitution | 2.07% | 888,130 | 13Fas of Mar 31, 2026 |
Acadian Asset Management LLCInstitution | 1.97% | 845,973 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Peter Blume-Jensen | director, officer: President and CEO | −14,036 | $2.21 |
| Aug 18, 2026 | Erick Gamelin | officer: Chief Development Officer | −400 | $2.01 |
| Aug 18, 2026 | Mary Miller | officer: Chief Legal Officer | −185 | $2.01 |
| Aug 18, 2026 | Katharine Peterson | officer: Chief Accounting Officer | −101 | $2.01 |
| Aug 18, 2026 | Peter Blume-Jensen | director, officer: President and CEO | −1,713 | $2.01 |
- Zentalis Pharmaceuticals
Late-stage WEE1 program in biomarker-selected ovarian cancer
- Aprea Therapeutics
WEE1 candidate in Phase 1 for serous endometrial and ovarian cancer
- Schrödinger
Dual WEE1/PKMYT1 Phase 1 program in advanced solid tumors
- Bristol-Myers Squibb
Phase I/II WEE1 CELMoD program for solid tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics | $2.15 | −0.23% | $92.0M | — | — | — | — |
| Zentalis Pharmaceuticals | $3.84 | +1.59% | $268.4M | — | — | — | — |
| Aprea Therapeutics | $0.8447 | +1.08% | $10.2M | — | — | — | +114.2% |
| Schrödinger | $20.72 | −0.77% | $1.56B | — | — | 6.0 | +7.5% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 14.9 | 10.6 | 4.4 | +7.5% |